[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address 54.158.167.137. Please contact the publisher to request reinstatement.
[Skip to Content Landing]
Medical News & Perspectives
July 22 2009

FDA Focuses on Drugs and Liver Damage

JAMA. 2009;302(4):369-371. doi:10.1001/jama.2009.1019

The US Food and Drug Administration (FDA) is working to reduce drug-induced liver damage with an initiative targeting the use of acetaminophen—the most common cause of such adverse events. The agency also is promoting research on genetic factors that may contribute to drug-related liver problems.

Drug-induced liver failure is a growing concern for the FDA. Cases of acute liver failure reported to the agency's Adverse Events Reporting System (AERS) have increased from 89 in 1995 to 404 in 2005, and acetaminophen is the drug most commonly implicated in such reports.

First Page Preview View Large
First page PDF preview
First page PDF preview
×